Zahir Amoura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zahir Amoura has a total of 664 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Mathian
Inserm UMRS, Centre d‘Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Groupement Hospitalier Pitié-Salpêtrière (GHPS) Service de Médecine Interne 2, Centre de Référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l‘adulte d‘Ile-de-France, Centre et Martinique, Institut E3M Paris
22 shared publications Julien Haroche
Sorbonne Université, Assistance Publique—Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, Centre National de Référence Pour le Lupus, le Syndrome des Anticorps Anti-Phospholipides et Autres Maladies Auto-Immunes Rares, Service de Médecine Interne 2, Institut E3M , Paris
15 shared publications- Guy Gorochov
Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), 75013 Paris, France
12 shared publications Micheline Pha
Sorbonne Université, Assistance Publique—Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, Centre National de Référence Pour le Lupus, le Syndrome des Anticorps Anti-Phospholipides et Autres Maladies Auto-Immunes Rares, Service de Médecine Interne 2, Institut E3M , Paris
12 shared publicationsAlexis Mathian
Department of Internal Medicine, Institute E3M, CIMI-Paris, Faculty of medicine, National Reference Centre of Systemic Lupus, Antiphospholipid Syndrome, and Other Autoimmune Diseases, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, boulevard de l'Hôpital, 75013 Paris, France
10 shared publications- Fleur Cohen Aubart
Internal Medicine Department 2, French Referral Center for Histiocytoses Assistance Publique–Hôpitaux de Paris Pitié–Salpêtrière Hospital, Sorbonne Université, Paris, France
9 shared publications
Latest Publications
- 23 October 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Characteristics of patients with isolated anti-Ku antibodies
- 23 October 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Characteristics of patients with isolated anti-Ku antibodies
- Open Access
- 17 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (5)
Ring-like late gadolinium enhancement pattern in antimalarial-induced cardiomyopathy
- 17 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (5)
Open AccessRing-like late gadolinium enhancement pattern in antimalarial-induced cardiomyopathy
- 13 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Lipid-rich pericoronary adipose tissue in systemic lupus erythematosus
- 13 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Lipid-rich pericoronary adipose tissue in systemic lupus erythematosus
- Open Access
- 10 May 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-14
CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?
Chimeric antigen receptor (CAR) T-cell therapy targeting B cells has shown promising results, including drug-free remission, in adult-onset autoimmune diseases. Extending this therapeutic approach to the pediatric population, particularly for juvenile autoimmune diseases, presents an exciting opportunity. However, challenges specific to juvenile-onset autoimmune conditions, such as long-term adverse events, heightened disease activity, and the imperative to reduce steroid exposure, must be considered. While this strategy appears viable for these severe conditions, the limited data available for this population and the absence of evidence on cases with a high genetic component, such as monogenic lupus, represent significant challenges. Most monogenic lupus cases are associated with innate immune defects, and the involvement of B cells in these genetic anomalies remains poorly understood. In this review, we examine the potential indications, current knowledge, and limitations of CAR-T cell therapy in juvenile-onset autoimmune diseases, extending the discussion beyond early-onset lupus.
- 10 May 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-14
Open AccessCAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?
Chimeric antigen receptor (CAR) T-cell therapy targeting B cells has shown promising results, including drug-free remission, in adult-onset autoimmune diseases. Extending this therapeutic approach to the pediatric population, particularly for juvenile autoimmune diseases, presents an exciting opportunity. However, challenges specific to juvenile-onset autoimmune conditions, such as long-term adverse events, heightened disease activity, and the imperative to reduce steroid exposure, must be considered. While this strategy appears viable for these severe conditions, the limited data available for this population and the absence of evidence on cases with a high genetic component, such as monogenic lupus, represent significant challenges. Most monogenic lupus cases are associated with innate immune defects, and the involvement of B cells in these genetic anomalies remains poorly understood. In this review, we examine the potential indications, current knowledge, and limitations of CAR-T cell therapy in juvenile-onset autoimmune diseases, extending the discussion beyond early-onset lupus.
- 13 February 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (7) , 4436-4437
Comment on: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis
- 13 February 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (7) , 4436-4437
Comment on: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis
- 6 January 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (8) , 2078-2082.e7
Identification of Serum IFN-α and BAFF Levels as Potential Biomarkers of Activity and Severity in Cutaneous Lupus Erythematosus
- 6 January 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (8) , 2078-2082.e7
Identification of Serum IFN-α and BAFF Levels as Potential Biomarkers of Activity and Severity in Cutaneous Lupus Erythematosus
- Open Access
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis
Background and aims Systemic sclerosis (SSc) is an autoimmune connective disease characterised by excessive extracellular matrix deposition and widespread skin and internal organ fibrosis including various cardiac manifestations. Heart involvement is one of the leading causes of death among patients with SSc. In this study, we aimed to assess the effect of various vasodilator treatments. Methods We used data from a national multicentric prospective study using the French SSc national database. We estimated the average treatment effect (ATE) of sildenafil, bosentan, angiotensin-converting enzyme (ACE) inhibitors and iloprost on diastolic dysfunction, altered ejection fraction Results We included 1048 patients with available data regarding treatment. Regarding sildenafil analyses, the ATE on diastolic dysfunction at 3 years was −2.83% (95% CI −4.06; −1.60, pConclusions Using causal methods, our study is the first and largest suggesting that sildenafil might have benefits among SSc patients regarding diastolic dysfunction and altered ejection fraction occurrence. However, further studies assessing the effect of vasodilators on heart-related outcome among SSc patients are needed to confirm those exploratory results.
Open AccessVasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis
Background and aims Systemic sclerosis (SSc) is an autoimmune connective disease characterised by excessive extracellular matrix deposition and widespread skin and internal organ fibrosis including various cardiac manifestations. Heart involvement is one of the leading causes of death among patients with SSc. In this study, we aimed to assess the effect of various vasodilator treatments. Methods We used data from a national multicentric prospective study using the French SSc national database. We estimated the average treatment effect (ATE) of sildenafil, bosentan, angiotensin-converting enzyme (ACE) inhibitors and iloprost on diastolic dysfunction, altered ejection fraction Results We included 1048 patients with available data regarding treatment. Regarding sildenafil analyses, the ATE on diastolic dysfunction at 3 years was −2.83% (95% CI −4.06; −1.60, pConclusions Using causal methods, our study is the first and largest suggesting that sildenafil might have benefits among SSc patients regarding diastolic dysfunction and altered ejection fraction occurrence. However, further studies assessing the effect of vasodilators on heart-related outcome among SSc patients are needed to confirm those exploratory results.
- 28 October 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (6) , 3906-3909
Lymphadenopathy in systemic lupus erythematosus: no microbial trigger found by shotgun metagenomics in a retrospective study on 38 patients
Objectives: Lymphadenopathy is a classical manifestation of SLE flare, occurring in approximately half of patients during the course of the disease. Lymphadenopathy in SLE is frequently associated with fever. Microbial infection may play a role in SLE onset and flares. The objectives of this study were to describe lymphadenopathy in the course of SLE and identify potential infectious triggers using microbial metagenomic analysis. Methods: We performed a retrospective monocentric study of 38 patients with SLE who had lymph node biopsy at baseline or during follow-up. Shotgun metagenomics were performed in the patient’s lymph node biopsy to look for microbial RNA and/or DNA. Results: Lymph node pathological analyses revealed follicular and/or paracortical hyperplasia in 73.7% of patients and histiocytic necrotizing lymphadenitis in 23.7%. At the time of biopsy, SLE patients exhibited fever in 29%, splenomegaly in 10%, cutaneous manifestations in 47%, polyarthritis in 32%, seritis in 13% and LN in 18%. Half of the patients (50%) had an increased CRP level, 35% had low C3, 65% had hypergammaglobulinemia. Microbial metagenomic analysis of lymph node biopsy revealed an absence of microbial DNA in 92% of patients, the presence of CMV in very small quantities in 2 patients, and the presence of HHV-7 in low quantities in a single patient. Conclusion: Despite suggestion that certain microorganisms may play a role in the pathogenesis and flares of SLE, our microbial metagenomic analysis study did not highlight possible infectious triggering factors. Further and better-designed studies are needed to confirm these results.
- 28 October 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (6) , 3906-3909
Lymphadenopathy in systemic lupus erythematosus: no microbial trigger found by shotgun metagenomics in a retrospective study on 38 patients
Objectives: Lymphadenopathy is a classical manifestation of SLE flare, occurring in approximately half of patients during the course of the disease. Lymphadenopathy in SLE is frequently associated with fever. Microbial infection may play a role in SLE onset and flares. The objectives of this study were to describe lymphadenopathy in the course of SLE and identify potential infectious triggers using microbial metagenomic analysis. Methods: We performed a retrospective monocentric study of 38 patients with SLE who had lymph node biopsy at baseline or during follow-up. Shotgun metagenomics were performed in the patient’s lymph node biopsy to look for microbial RNA and/or DNA. Results: Lymph node pathological analyses revealed follicular and/or paracortical hyperplasia in 73.7% of patients and histiocytic necrotizing lymphadenitis in 23.7%. At the time of biopsy, SLE patients exhibited fever in 29%, splenomegaly in 10%, cutaneous manifestations in 47%, polyarthritis in 32%, seritis in 13% and LN in 18%. Half of the patients (50%) had an increased CRP level, 35% had low C3, 65% had hypergammaglobulinemia. Microbial metagenomic analysis of lymph node biopsy revealed an absence of microbial DNA in 92% of patients, the presence of CMV in very small quantities in 2 patients, and the presence of HHV-7 in low quantities in a single patient. Conclusion: Despite suggestion that certain microorganisms may play a role in the pathogenesis and flares of SLE, our microbial metagenomic analysis study did not highlight possible infectious triggering factors. Further and better-designed studies are needed to confirm these results.
- Open Access
- 27 August 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (9) , 559-599
French protocol for the diagnosis and management of systemic lupus erythematosus
- 27 August 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (9) , 559-599
Open AccessFrench protocol for the diagnosis and management of systemic lupus erythematosus